ARS Pharmaceuticals, Inc. SPRY Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $24.32M-39.0% | $41.32M-18.7% | $59.56M+50.2% | $51.54M+40.7% | $39.86M-28.8% | ||
| $176.65M-25.1% | $203.67M-22.6% | $228.65M+38.6% | $188.59M+3.6% | $235.86M+40.7% | ||
| $28.66M+208% | $25.35M+210% | $36.45M+4,616% | $25.13M— | $9.3M— | ||
| $23.22M+94.5% | $23.05M+334% | $13.65M+1,808% | $13.37M— | $11.94M— | ||
| $245.24M-19.3% | $284.9M-14.8% | $338.86M+62.3% | $281.44M+27.5% | $303.86M+34.3% | ||
| $2.29M+113% | $2.47M+131% | $1.21M+43.4% | $1.08M+69.0% | $1.08M+74.5% | ||
| $14.18M— | $14.45M— | $14.73M— | $12.97M— | —— | ||
| $287.57M-12.1% | $327.65M-6.7% | $372.8M+71.3% | $313.47M+41.2% | $327.32M+43.8% | ||
| $48.26M+78.7% | $37.95M+66.1% | $49.77M+201% | $44.26M+574% | $27.01M+672% | ||
| $757K— | $609K— | $526K— | —— | —— | ||
| $49.61M+79.6% | $39.15M+67.0% | $50.88M+206% | $45.6M+578% | $27.62M+644% | ||
| —— | —— | —— | —— | —— | ||
| $226.26M+130% | $213.39M+126% | $225.15M+1,254% | $121.15M+1,702% | $98.34M+2,547% | ||
| $10K0.0% | $10K0.0% | $10K0.0% | $10K0.0% | $10K0.0% | ||
| -$355.22M-126% | -$294.6M-139% | -$253.28M-46.2% | -$202.13M-31.2% | -$157.25M-11.1% | ||
| $61.31M-73.2% | $114.26M-55.5% | $147.66M-26.5% | $192.32M-10.6% | $228.97M+2.3% | ||
| $287.57M-12.1% | $327.65M-6.7% | $372.8M+71.3% | $313.47M+41.2% | $327.32M+43.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are ARS Pharmaceuticals, Inc.'s total assets?
- ARS Pharmaceuticals, Inc. (SPRY) holds $287.6M in total assets, down 12.1% year over year.
- How much debt does ARS Pharmaceuticals, Inc. have?
- ARS Pharmaceuticals, Inc. carries $96.5M in total debt against $61.3M of shareholders' equity, a debt-to-equity ratio of 1.57.
- How much cash does ARS Pharmaceuticals, Inc. have?
- ARS Pharmaceuticals, Inc. holds $24.3M in cash and equivalents.
- Can ARS Pharmaceuticals, Inc. cover its short-term obligations?
- Its current ratio is 4.94 — current assets exceed current liabilities.
- Where does ARS Pharmaceuticals, Inc.'s balance sheet data come from?
- Every line is extracted from ARS Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
